Tech Company Financing Transactions
Melinta Therapeutics Funding Round
On 6/20/2006, Melinta Therapeutics received $50 million in Series C funding from Warburg Pincus, ABS Capital Partners and Axiom Venture Partners.
Transaction Overview
Company Name
Announced On
6/20/2006
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
Warburg Pincus (Lead Investor) (Stewart Hen)
Radius Ventures (Wayne Hockmeyer)
Proceeds Purpose
These new funds will fuel the advancement of our two active clinical-stage programs and further the build out of our pipeline of new antibiotic clinical candidates derived from the company's proprietary high-resolution x-ray crystallography and computational chemistry technologies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 George St. 301
New Haven, CT 06511
USA
New Haven, CT 06511
USA
Phone
Website
Email Address
Overview
Melinta Therapeutics' mission is to discover, develop and commercialize groundbreaking antibiotics to overcome drug-resistant, life-threatening infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christine Miller
Chief Financial Officer
Peter Milligan
VP - Bus. Development
Michael McGuire
VP - Finance
Susan Blum
VP - General Counsel
Jennifer Sanfilippo
Browse more venture capital transactions:
Prev: 6/19/2006: Acopia Networks venture capital transaction
Next: 6/20/2006: Autotask venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs